Kymera marches protein-degrading drugs toward clinic with $102M raise

Illustration of proteins
Kymera’s approach makes use of the body’s protein degradation machinery to get rid of disease-causing proteins. (Kymera Therapeutics)

Kymera Therapeutics is plotting a big transition in 2020. After spending four years building the company around its protein degradation technology, it’s setting its sights on the clinic—and it’s just bagged $102 million to do so. 

The series C round comes from a group of “top-tier investors” including Biotechnology Venture Fund, Redmile Group and Bain Capital that are “aligned with the mission of the company, which is the discovery, development and also the commercialization of degrader drugs,” CEO and co-founder Nello Mainolfi told FierceBiotech. 

Kymera’s approach makes use of the body’s protein degradation machinery to get rid of disease-causing proteins. The new capital will see up to three programs into human trials over the next 12 to 16 months, Mainolfi said. It will also fund the ongoing development of its protein degradation platform, dubbed Pegasus, allowing the company to discover and advance new treatments. 

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

RELATED: FierceBiotech’s 2019 Fierce 15 | Kymera Therapeutics 

Cambridge, Massachusetts-based Kymera has disclosed two targets it’s attacking in cancer and inflammatory and immunological diseases. Its lead program targets IRAK4, a protein involved in disease signaling pathways. The company plans to test the treatment in healthy volunteers at the end of this year or early next year, Mainolfi said. 

After that, Kymera will move the treatment into its first disease indication, hidradenitis suppurativa, a chronic inflammatory disease that affects the sweat glands and has no cure. Current treatments vary from patient to patient and depend on the severity of their disease. Around the same time, sometime in mid-2021, Kymera will start testing the IRAK4 program in lymphoma patients whose cancer is driven by mutation in the gene MYD88. Kymera also picked up funding from The Leukemia & Lymphoma Society's Therapy Acceleration Program for its blood cancer efforts. 

RELATED: Kymera rolls out new animal data on its lead protein-degradation drug to treat lymphoma 

The company’s second program targets the transcription factor STAT3, which plays a role in autoimmune and inflammatory diseases as well as cancer. Its first focus will be blood cancers, but it plans to move into solid tumors later, Mainolfi said. 

As it pushes its treatments through the clinic and toward patients, Kymera will apply that experience to its earlier-stage pipeline: “We have the ability to learn and translate that back to inform the next wave of degrader programs,” Mainolfi said.

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Evidation Health is pairing up with BARDA to develop a digital means of detecting a person’s early symptoms of COVID-19.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.